Israel Englander’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $3.79M | Buy |
+46,494
| New | +$3.36M | ﹤0.01% | 3259 |
|
|
2026
Q1 | – | Sell |
-22,494
| Closed | -$1.71M | – | 6249 |
|
|
2025
Q4 | $1.71M | Sell |
22,494
-1,033,987
| -98% | -$75.1M | ﹤0.01% | 4083 |
|
|
2025
Q3 | $64.8M | Buy |
1,056,481
+672,079
| +175% | +$35M | 0.03% | 686 |
|
|
2025
Q2 | $18.8M | Buy |
384,402
+159,563
| +71% | +$7.57M | 0.01% | 1625 |
|
|
2025
Q1 | $11.5M | Sell |
224,839
-84,584
| -27% | -$4.22M | 0.01% | 2047 |
|
|
2024
Q4 | $14M | Buy |
309,423
+89,959
| +41% | +$3.85M | 0.01% | 1845 |
|
|
2024
Q3 | $8.14M | Sell |
219,464
-98,115
| -31% | -$3.28M | ﹤0.01% | 2385 |
|
|
2024
Q2 | $9.71M | Buy |
317,579
+175,289
| +123% | +$5.68M | ﹤0.01% | 2105 |
|
|
2024
Q1 | $4.14M | Sell |
142,290
-368,286
| -72% | -$10.3M | ﹤0.01% | 3065 |
|
|
2023
Q4 | $14.1M | Buy |
510,576
+403,686
| +378% | +$9.23M | 0.01% | 1878 |
|
|
2023
Q3 | $2.4M | Buy |
106,890
+100,029
| +1,458% | +$3.72M | ﹤0.01% | 3385 |
|
|
2023
Q2 | $279K | Buy |
+6,861
| New | +$336K | ﹤0.01% | 4936 |
|
|
2023
Q1 | – | Sell |
-299,133
| Closed | -$13.7M | – | 6752 |
|
|
2022
Q4 | $11.4M | Sell |
299,133
-142,220
| -32% | -$5.91M | 0.01% | 1978 |
|
|
2022
Q3 | $22.2M | Buy |
+441,353
| New | +$21.6M | 0.01% | 1257 |
|
|
2022
Q1 | – | Sell |
-25,854
| Closed | -$1.03M | – | 7368 |
|
|
2021
Q4 | $1.03M | Buy |
25,854
+13,418
| +108% | +$514K | ﹤0.01% | 4380 |
|
|
2021
Q3 | $463K | Buy |
12,436
+6,735
| +118% | +$277K | ﹤0.01% | 5425 |
|
|
2021
Q2 | $241K | Sell |
5,701
-145,077
| -96% | -$6.22M | ﹤0.01% | 5897 |
|
|
2021
Q1 | $7.14M | Buy |
150,778
+135,331
| +876% | +$8.04M | 0.01% | 2175 |
|
|
2020
Q4 | $943K | Buy |
+15,447
| New | +$910K | ﹤0.01% | 3783 |
|
|
2020
Q2 | – | Sell |
-39,682
| Closed | -$1.77M | – | 4518 |
|
|
2020
Q1 | $1.77M | Sell |
39,682
-40,159
| -50% | -$2.02M | ﹤0.01% | 2104 |
|
|
2019
Q4 | $3.83M | Sell |
79,841
-119,038
| -60% | -$5.06M | ﹤0.01% | 2145 |
|
|
2019
Q3 | $6.73M | Sell |
198,879
-1,034,449
| -84% | -$45M | 0.01% | 1579 |
|
|
2019
Q2 | $55.5M | Buy |
1,233,328
+695,327
| +129% | +$27.5M | 0.08% | 301 |
|
|
2019
Q1 | $20.3M | Buy |
538,001
+374,690
| +229% | +$12.6M | 0.03% | 792 |
|
|
2018
Q4 | $5.61M | Sell |
163,311
-184,434
| -53% | -$6.63M | 0.01% | 1510 |
|
|
2018
Q3 | $16.3M | Sell |
347,745
-76,161
| -18% | -$3.15M | 0.02% | 955 |
|
|
2018
Q2 | $14.3M | Sell |
423,906
-253,595
| -37% | -$7.91M | 0.02% | 1083 |
|
|
2018
Q1 | $18.3M | Buy |
677,501
+122,296
| +22% | +$3.1M | 0.02% | 927 |
|
|
2017
Q4 | $9.26M | Buy |
555,205
+294,572
| +113% | +$4.99M | 0.01% | 1377 |
|
|
2017
Q3 | $5.21M | Buy |
+260,633
| New | +$5.1M | 0.01% | 1649 |
|
|
2017
Q2 | – | Sell |
-748,105
| Closed | -$7.36M | – | 3780 |
|
|
2017
Q1 | $7.36M | Sell |
748,105
-787,462
| -51% | -$9.53M | 0.01% | 1214 |
|
|
2016
Q4 | $16.8M | Buy |
1,535,567
+1,291,030
| +528% | +$13.5M | 0.04% | 661 |
|
|
2016
Q3 | $3.43M | Buy |
244,537
+192,535
| +370% | +$1.57M | 0.01% | 1593 |
|
|
2016
Q2 | $365K | Sell |
52,002
-501,959
| -91% | -$3.68M | ﹤0.01% | 2638 |
|
|
2016
Q1 | $3.57M | Buy |
+553,961
| New | +$9.61M | 0.01% | 1446 |
|
|
2015
Q4 | – | Sell |
-269,419
| Closed | -$7.93M | – | 3706 |
|
|
2015
Q3 | $7.19M | Sell |
269,419
-22,022
| -8% | -$942K | 0.01% | 1130 |
|
|
2015
Q2 | $14M | Buy |
+291,441
| New | +$17M | 0.03% | 786 |
|
|
2015
Q1 | – | Sell |
-31,030
| Closed | -$1.89M | – | 3995 |
|
|
2014
Q4 | $1.61M | Sell |
31,030
-320,704
| -91% | -$14.1M | ﹤0.01% | 2147 |
|
|
2014
Q3 | $15.5M | Sell |
351,734
-95,147
| -21% | -$2.98M | 0.04% | 624 |
|
|
2014
Q2 | $11.7M | Buy |
+446,881
| New | +$9.57M | 0.03% | 746 |
|
Other funds holding PTCT
RI
JT
Israel Englander's PTCT Position: Q2 2026 in Review
Israel Englander opened a new position in PTC Therapeutics (PTCT) in Q2 2026: 46,494 shares worth $3.79M. The stake represents ﹤0.01% of the portfolio and ranks #3259 among its holdings. This is a return to the name: Israel Englander previously reported a position in PTCT as recently as Q4 2025.
Israel Englander first reported a position in PTCT in Q2 2014 and has held it in 40 quarters since. The position peaked at $64.8M in Q3 2025. 380 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Israel Englander held 46,494 shares of PTC Therapeutics worth $3.79M as of Q2 2026.
- PTC Therapeutics was a new Israel Englander position in Q2 2026.
- PTC Therapeutics made up ﹤0.01% of Israel Englander's portfolio in Q2 2026, its #3259 holding.
- Israel Englander first reported a position in PTC Therapeutics in Q2 2014 and has held it in 40 quarters since.
- Israel Englander's PTC Therapeutics position peaked at $64.8M in Q3 2025.
- 380 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Millennium Management's 13F filing for Q2 2026, filed 14 Aug 2026.